Introduction {#S1}
============

Otitis media (OM) is defined as an infective and inflammatory disorder of the middle ear. While OM is associated with significant heterogeneity in clinical presentation, the broad types include acute otitis media (AOM), chronic suppurative otitis media (CSOM), and chronic otitis media with effusion (OME). Previous studies have shown that the pooled incidence of AOM is about 11% worldwide, with 51% of cases occurring in children under the age of five ([@B54]). The recurrence of AOM may lead to OME, which has a worldwide incidence rate of up to 5% ([@B54]). Both AOM and OM continue to be associated with healthcare utilization in the form of antibiotic therapy, physician and emergency room visits, and common surgical procedures such as tympanostomy tubes, although the advent of effective antimicrobial therapy has led to a substantial reduction in the burden of CSOM ([@B87]). A smaller number of studies have also described an association between middle ear infections and speech and language deficits, emphasizing the role of OM in childhood development ([@B70]).

The most common bacteria isolated from the middle ear of patients with AOM include *Streptococcus pneumoniae* and *Haemophilus influenzae*, although *Moraxella catarrhalis*, *Streptococcus pyogenes*, and *Staphylococcus aureus* are less frequently observed. In contrast, *Pseudomonas aeruginosa* and *S. aureus* are the most frequently observed pathogens in CSOM ([@B31]).

OM is a multifactorial disorder that may be attributed to a combination of etiologic factors including immunologic, genetic, environmental, and anatomic characteristics. Seasonal microbial susceptibility and Eustachian tube dysfunction are the commonly observed causes ([@B84]; [@B26]). It is well-known that viruses from the respiratory airways also play a crucial role in the pathogenesis of AOM ([@B61]). Further, exposure to tobacco smoke, the use of a pacifier, and daycare attendance are among the risk factors for OM, while breastfeeding and pneumococcal vaccines have protective effects ([@B84]; [@B50]; [@B1]; [@B62]).

Beyond environmental factors, genetic background also confers susceptibility to OM, although the disease mechanism is not fully understood. Several OM-associated genes, identified through studies in humans and in animal models, are known to play fundamental roles in diverse biological processes including (1) the development of the middle ear cleft and the Eustachian tube, (2) immune response, (3) bacterial adhesion and viral infection rate, (4) regulation of extracellular matrix, and (5) clearance of pathogens (see [Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} for specific studies). In this review, we summarized the genomic variants and factors that have been reported in patients with various forms of OM. Early genetic association studies, mouse, mouse-to-man, human candidate, and genome-wide association studies that correlate OM and genetic variations are also briefly discussed. However, we particularly focused on the recent findings of the associations of A2ML1 and FUT enzymes with OM and offered our perspective on the potential disease mechanism that intuitively can lead to OM in individuals harboring variants of *FUT2*.

###### 

Most common loci associated with otitis media in mouse studies.

  **Locus**      **Protein**                                                        **Protein function/phenotype in mouse mutant**                                                                                                                                                     **OMIM**   **References**
  -------------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------- ----------------
  *C3H/Hej*      *TLR4* mice strain                                                 *TLR4* mice are prone to bacterial infection                                                                                                                                                       603030     [@B53]
  *Ccl3*         C-C motif chemokine 3                                              Downstream of TNF-mediated inflammation pathways                                                                                                                                                   182283     [@B47]
  *Cfb*          Complement factor B                                                *Streptococcus pneumoniae* induced increased gene expression of factor B of the alternative complement pathway and C3 in mouse middle ear epithelium                                               138470     [@B48]
  *Chd7*         Chromodomain-helicase-DNA-binding protein 7                        OM with effusion                                                                                                                                                                                   608892     [@B90]
  *Eda*          Ectodysplasin-A                                                    Otitis media, rhinitis, and nasopharyngitis                                                                                                                                                        300451     [@B7]
  *Edar*         Tumor necrosis factor receptor superfamily member EDAR             Otitis media, rhinitis, and nasopharyngitis                                                                                                                                                        604095     [@B7]
  *Enpp1*        Ectonucleotide pyrophosphatase/phosphodiesterase family member 1   OM with effusion in *Enpp1*^*asj*^ mutant mice                                                                                                                                                     173335     [@B88]
  *Ets1*         E26 transformation-specific 1                                      Craniofacial abnormalities, small middle ear cavity, short nasal bone, hearing impairment, otitis media, fusion of ossicles to the middle ear wall, and deformed stapes                            164720     [@B12]
  *Evi1*         Ectotropic viral integration 1                                     Chronic suppurative OM with otorrhea                                                                                                                                                               165215     [@B64]
  *Eya4*         Eyes absent homolog 4                                              Abnormal middle ear cavity and Eustachian tube                                                                                                                                                     603550     [@B19]
  *Fbxo11*       F-box only protein 11                                              Compound heterozygotes carrying both Jeff and Mutt alleles demonstrated a shortened face, reduced hearing, and OM                                                                                  607871     [@B35]
  *Fli1*         Friend leukemia integration 1 transcription factor                 Craniofacial abnormalities, small middle ear cavity, short nasal bone, hearing impairment, otitis media, fusion of ossicles to the middle ear wall, and deformed stapes                            193067     [@B12]
  *Hbegf*        Heparin binding EGF- like growth factor                            Mucosal epithelial hyperplasia                                                                                                                                                                     126150     [@B83]
  *Hif*          Hypoxia inducible factor                                           Hypoxia and signal abruptions                                                                                                                                                                      603348     [@B14]
  *Jnk1*         JNK1                                                               C57BL/6 mice deficient in JNK1 exhibit enhanced mucosal thickening                                                                                                                                 601158     [@B98]
  *Jnk2*         JNK2                                                               JNK2-/- mice exhibit delayed mucosal hyperplasia, delayed recruitment of neutrophils, and failure of bacterial clearance                                                                           602896     [@B98]
  *Lysozyme M*   Lysozyme M                                                         *Lysozyme M* deficiency leads to an increased susceptibility to *Streptococcus pneumoniae*-induced OM                                                                                              153450     [@B81]
  *Lmna*         Prelamin-A/C                                                       Malformation and abnormal positioning of the Eustachian tube, accompanied by OM, were observed in all of the Lmna(Dhe/+) mutant mice                                                               150330     [@B99]
  *MyD88*        Myeloid differentiation primary response protein MyD88             Delayed recruitment of neutrophils and macrophages                                                                                                                                                 602170     [@B36]
  *Mcp1/Ccl2*    C-C motif chemokine 2                                              MCP-1/CCL2 contributes to inner ear inflammation secondary to NTHi -induced OM                                                                                                                     158105     [@B96]
  *Math1*        Protein atonal homolog 1                                           Important for mucous cell differentiation                                                                                                                                                          601461     [@B59]
  *Mph1*         Sex comb of midleg                                                 OM with effusion in the hearing-impaired Mcph1(tm1a) (/tm1a) mutant mice                                                                                                                           300227     [@B15]
  *Oxgr1*        2-Oxoglutarate receptor 1                                          COME                                                                                                                                                                                               606922     [@B41]
  *Pai1*         Plasminogen activator inhibitor 1                                  Bullae of PAI-1 mutant mice showed low levels of inflammation against NTHi at the early stage of OM                                                                                                173360     [@B82]
  *Pax9*         Paired box protein Pax-9                                           Expression reduced in Slc25a21(tm1a(KOMP)Wtsi) mutant mice; leads to inflammation of the middle ear                                                                                                167416     [@B52]
  *Phex*         Phosphate-regulating neutral endopeptidase PHEX                    Mutation in *Phex* gene predisposes the BALB/c-Phex(Hyp-Duk)/Y mice to OM                                                                                                                          300550     [@B33]
  *Plg*          Plasminogen                                                        Infiltration of neutrophils and macrophages as well as the presence of T and B cells in the middle ear mucosa                                                                                      173350     [@B24]
  *Spag6*        Sperm-associated antigen 6                                         *Spag6* mutant mice are prone to develop OM due to accumulation of fluid and mucus secondary to the ciliary dysfunction.                                                                           605730     [@B49]
  *Sh3pxd2b*     SH3 and PX domain-containing protein 2B                            Sh3pxd2b(nee) mutant mice develop craniofacial dysmorphologies and OM changes in cilia and goblet cells of the middle ear mucosa in Sh3pxd2b(nee) mutant mice were observed                        613293     [@B97]
  *Slc25a21*     Solute carrier Family 25 member 21                                 Homozygosity for Slc25a21(tm1a(KOMP)Wtsi) results in mice exhibiting orofacial abnormalities, alterations in carpal and rugae structures, hearing impairment, and inflammation in the middle ear   607571     [@B52]

###### 

Most common loci associated with otitis media in human studies.

  **Gene**    **Chr:**   **Protein**                                                **Function/pathway**                                                         **Marker**                                                                                     **Country**                  **Sample size**                                                                                  **Significance**                                                                                                **Clinical outcome**                                                                                               **References**
  ----------- ---------- ---------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------ ----------------
  *A2ML1*     12         Alpha-2-macroglobulin-like protein 1 (A2ML1)               Peptidase inhibitor activity                                                 c.2478_2485dupGG CTAAAT (p.Ser829Trpfs\*9), p.Glu972\*                                         Philippines                  Familial (affected = 38, unaffected = 13)                                                        LOD = 7.5                                                                                                       OM                                                                                                                 [@B76]
  *ABO*       9          Histo-blood group ABO system transferase                   Blood type                                                                   Type O: c.260insG(p.Val87\_ Thr88fs\*) Type A                                                  Finland                      214 probands                                                                                     Type A: (OR = 2.14; 95% CI: 1.04--4.50; *p* = 0.03) type O: (OR = 0.33; 95% CI: 0.11--1.04; *p* = 0.04)         RAOM/COME A increases risk for COME c.260insG (p.Val87_Thr88fs\*) variant and type O are protective against RAOM   [@B95]
  *CD14*      5          Cluster of differentiation 14 (CD14)                       Immune response, co-receptor of TRL4                                         rs2569190                                                                                      Netherlands                  ca = 74, co = 35                                                                                 *p* = 0.004                                                                                                     AOM                                                                                                                [@B93]
  *CPT1A*     11         Carnitine palmitoyl transferase type 1A (CPT1A)            Fatty acid oxidation                                                         rs80356779                                                                                     Alaska                       ca = 291, co = 136                                                                               *p* \< 0.001                                                                                                    OM                                                                                                                 [@B30]
  *CX3CR1*    3          CX3C chemokine receptor 1                                  Binds to chemokine                                                           rs3732378                                                                                      USA                          ca = 653                                                                                         *p* = 0.038                                                                                                                                                                                                                        [@B60]
  *FBXO11*    2          F-box only protein 1 (FBXO11)                              Protein ubiquitination                                                       rs10182633 rs12620679 rs12712997 rs13430439 rs2710163 rs33787 rs6713506 rs6728843 rs12712997   Australia                    ca = 253, co = 866                                                                               *p* = 0.0009 *p* = 0.001 *p* = 0.0002 *p* = 0.0061 *p* = 0.0003 *p* = 6.9 × 10^--6^ *p* = 0.0074 *p* = 0.0061   AOM                                                                                                                [@B72]
                                                                                                                                                                 rs330787                                                                                                                    ca = 434 families, co = 561                                                                      *p* = 0.009 *p* = 0.053                                                                                         RAOM/COME                                                                                                          
  *FCGR2A*    1          Fc gamma receptor 11a (FCGR2A)                             Fc gamma receptor, immune response                                           rs1801274                                                                                      Netherlands                  ca = 383                                                                                         *p* = 0.03                                                                                                      OM after PV                                                                                                        [@B94]
  *FNDC1*     6          Fibronectin type III domain-containing protein 1 (FNDC1)   May be an activator of G protein signaling                                   rs2932989                                                                                      European                     825 cases and 7,936 control                                                                      *p*~*meta*~ = 2.15 × 10^--09^                                                                                   AOM                                                                                                                [@B92]
  *FUT2*      19         Galactoside 2-alpha-L-fucosyltransferase 2 (FUT2)          Creates H antigen, essential for the formation of ABO blood group antigens   rs1800022, rs601338, rs149356814, rs602662                                                     Philippines, Pakistan, USA   1 Filipino consanguineous pedigree 609 multi-ethnic families and simplex case subjects with OM   LOD = 4.0                                                                                                       COME, AOM, OM                                                                                                      [@B75]
  *IFNG*      12         IFN γ                                                      Cytokines, immune response                                                   rs2430561                                                                                      USA                          ca = 20, co = 57                                                                                 *p* = 0.04                                                                                                      OM with RSV infection                                                                                              [@B29]
  *IL10*      1          Interleukin 10 (IL-10)                                     Cytokines, immune response                                                   rs1554286, rs1800872, rs1800890, rs1800893, rs1800896, rs3024509                               USA                          142 families                                                                                     p(ht) = 0.012, p(ht) = 0.039, p(ht) = 0.017, p(ht) = 0.017, p(ht) = 0.017, *p* = 0.040                          RAOM/COME                                                                                                          [@B74]
                                                                                                                                                                 rs1800896                                                                                      Netherlands                  ca = 348, co = 463                                                                               *p* = 0.01                                                                                                      Protective for AOM after PV                                                                                        [@B23]
                                                                                                                                                                 rs1800871                                                                                      Greece                       ca = 96, c = nil                                                                                 *p* \< 0.0001                                                                                                   AOM                                                                                                                [@B37]
                                                                                                                                                                 rs1800896, rs1800871, rs1800872                                                                USA                          ca = 102, co = 98                                                                                *p* = 0.005 *p* = 0.05 *p* = 0.05                                                                               OM followed RSV/RV                                                                                                 
  *IL1A*      2          Interleukin I- (IL-1 alpha)                                Cytokines, immune response                                                   rs1800587                                                                                      Finland                      ca = 63, co = 400                                                                                *p* = 0.03                                                                                                      RAOM                                                                                                               [@B38]
  *IL1B*      2          Interleukin 1-β (IL-1β)                                    Cytokines, immune response                                                   rs16944                                                                                        USA                          ca = 653, co = nil                                                                               OR = 1.35                                                                                                       OM (prone)                                                                                                         [@B60]
                                                                                                                                                                 rs1143634                                                                                                                   ca = 104, co = 24                                                                                *p* = 0.02                                                                                                      AOM (inflammation)                                                                                                 
  *IL6*       7          Interleukin 6 (IL--6)                                      Cytokines, immune response                                                   rs1800795                                                                                      Netherlands                  ca = 347, co = 460                                                                               OR \> 1.45; *p* = 0.02                                                                                          AOM                                                                                                                [@B23]
                                                                                                                                                                 rs1800795                                                                                      USA                          ca = 68, co = 145                                                                                *p* \< 0.01                                                                                                     RAOM                                                                                                               [@B69]
                                                                                                                                                                 rs1800795                                                                                      USA                          ca = 192, co = 192                                                                               *p* = 0.03                                                                                                      AOM                                                                                                                [@B65]
                                                                                                                                                                 rs1800795                                                                                      USA                          ca = 77, co = 80                                                                                 *p* \< 0.01                                                                                                     AOM                                                                                                                [@B60]
  *MBL2*      10         Mannose-binding lectins (MBL)                              Immune response                                                              rs11003125, rs1800450, rs1800451, rs5030737, rs7095891, rs7096206                              Belgium                      ca = 17, co = 172                                                                                OR(ht) = 2.9                                                                                                    AOM                                                                                                                [@B63]
  *mDNA*      mt         n/a                                                        Mitochondrial DNA                                                            p.Thr195Cys                                                                                    Czech Republic               ca = 355                                                                                         *p* = 0.032                                                                                                     AOM                                                                                                                [@B74]
  *MUC2*      11         Mucin-2                                                    Gel-forming mucin, lubrication, viscoelasticity                              rs7396030                                                                                      USA                          142 families                                                                                     *p* = 0.049                                                                                                     RAOM/COME                                                                                                          [@B74]
                                                                                                                                                                 rs7396030                                                                                      USA                          441 families                                                                                     *p* = 0.022                                                                                                     RAOM/COME                                                                                                          
  *MUC5AC*    11         Mucin-5AC                                                  Gel-forming mucin, lubrication, viscoelasticity                              MUC5AC (intronic)                                                                              USA                          ca = 40, co = 40                                                                                 *p* = 0.025                                                                                                     RAOM/COME                                                                                                          [@B91]
  *MUC5B*     11         Mucin-5B                                                   Gel-forming mucin, lubrication, viscoelasticity                              rs4963049                                                                                      USA                          ca = 102, co = 83                                                                                *p* = 0.033                                                                                                     COME                                                                                                               [@B51]
                                                                                                                                                                 rs2075859                                                                                      USA                          142 families                                                                                     *p* = 0.041                                                                                                     RAOM/COME                                                                                                          [@B74]
                                                                                                                                                                 rs2735733                                                                                      USA                          142 families                                                                                     *p* = 0.02                                                                                                      RAOM/COME                                                                                                          [@B74]
  *PAI1*      7          Plasminogen activator inhibitor-1 (PAI1)                   Inflammation                                                                 rs1799889                                                                                      Netherlands                  ca = 226, co = 122                                                                               *p* = 0.02                                                                                                      RAOM                                                                                                               [@B23]
  *SCN1B*     19         Sodium channel sub-unit β1 (SCN~1~β)                       Ion channel binding, voltage-gated ion channel activity                      rs8100085                                                                                      USA                          ca = 142 families                                                                                *p* = 0.013                                                                                                     RAOM/COME                                                                                                          [@B74]
  *SFTPA1*    10         SFTPA1                                                     Phospho-lipoproteins, surfactant                                             sa4-1a haplotype                                                                               Finland                      ca = 147,co = 278                                                                                p(ht) = 0.03                                                                                                    RAOM                                                                                                               [@B67]
  *SFTPD*     10         SFTPD                                                      Phospho-lipoproteins, surfactant                                             RS1051246                                                                                      USA                          142 families                                                                                     *p* = 0.039                                                                                                     RAOM/COM                                                                                                           [@B74]
  *SLC11A1*   2          Solute carrier family 11 member (SLC11A1)                  Transporter, pathogen clearance                                              rs2276631, rs02695343, rs34448891, rs3731865                                                   Australia                    ca = 531 families, co = 660                                                                      p(ht) = 0.008                                                                                                   OM Proneness                                                                                                       [@B73]
  *SMAD2*     18         SMAD2                                                      Transcriptional modulator activated by TGF-beta                              rs1792658                                                                                      Australia                    ca = 434 families, co = 561                                                                      *p* = 0.038                                                                                                     RAOM/COME                                                                                                          [@B72]
  *SMAD4*     18         SMAD4                                                      Transcriptional modulator activated by BMP                                   rs10502913                                                                                     Australia                    ca = 434 families, co = 561                                                                      *p* = 0.048                                                                                                     RAOM/COME                                                                                                          [@B72]
  *TGFB1*     19         Transforming growth factor beta 1 (TGF-β1)                 Antigen binding, immune response                                             rs1982073                                                                                      Greece                       ca = 96                                                                                          *p* = 0.002                                                                                                     AOM                                                                                                                [@B37]
  *TLR2*      4          Toll-like receptor 2 (TLR2)                                Inflammation, initiators of innate immunity system                           rs5743708                                                                                      Serbia                       ca = 85, co-100                                                                                  Significantly high                                                                                              COME                                                                                                               [@B45]
  *TLR4*      9          Toll-like receptor 4 (TLR4)                                Inflammation, initiators of innate immunity system                           rs1800896, rs1800871, rs1800872                                                                USA                          ca = 172, co = 83                                                                                *p* = 0.005 *p* = 0.05 *p* = 0.05                                                                               AOM                                                                                                                [@B37]
                                                                                                                                                                 rs11788318, rs4837494, rs10116253, rs1927914, rs1554973                                        USA                          ca = 102, co = 83                                                                                *p* = 0.008, *p* = 0.031, *p* = 0.007, *p* = 0.023, *p* = 0.021                                                 COME                                                                                                               [@B51]
                                                                                                                                                                 rs10116253, rs12377632, rs22770146, rs5030717                                                  USA                          142 families                                                                                     p (ht) = 0.025, p(ht) = 0.014, *p* = 0.026, p(ht) = 0.017                                                       COME/RAOM                                                                                                          [@B74]
                                                                                                                                                                 rs5030717, rs1329060, rs1329057                                                                Finland                      ca = 624, co = 778 1,269 trios 403 families ca = 100, co = 104                                   OR 1.33, *p* = 0.003 OR 1.33, *p* = 0.002 OR 1.29, *p* = 0.003                                                  COME/RAOM                                                                                                          [@B32]
  *TNFA*      6          Tumor necrosis factor α (TNF α)                            Cytokines, immune response                                                   rs1800629                                                                                      USA                          ca = 192, co = 192                                                                               *p* = 0.05                                                                                                      AOM                                                                                                                [@B23]
                                                                                                                                                                                                                                                                                             ca = 222, co = 120                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                Netherlands                                                                                                                   *p* = 0.07                                                                                                      AOM                                                                                                                [@B69]
                                                                                                                                                                 rs1800750                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                             ca = 68, co = 145                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                              OR = 1.42                                                                                                       RAOM                                                                                                               [@B69]
                                                                                                                                                                 rs1800750                                                                                      USA                                                                                                                                                                                                                                                                                                                                                              

Ca, cases; Co, controls; OR, odds ratio; p, p-value; LOD, logarithm of the odds.

Early Studies {#S1.SS1}
-------------

The genetic contribution to OM susceptibility became evident in the 1980s after several studies showed that the prevalence of OM was disproportionately high in some ethnicities (native Americans and Australian aborigines) and relatively low in individuals of African ancestry ([@B16]; [@B8]). A surveillance study on ear and nasopharyngeal carriage was conducted among remote Australian aboriginal communities in 2013 and found that 50% of young children (mean age 13 months) had OME, 37% had AOM, and 12% had CSOM ([@B44]). Today, CSOM continues to be strongly implicated in the prevalence of hearing and learning disorders in Australian aboriginal communities ([@B55]).

One of the earliest genetic studies on OM, conducted in 1983, analyzed the blood groups (ABO) in a cohort of 610 children with chronic otitis media with effusion (COME) and concluded that blood group "A" was a genetic risk factor for OM based on their observation of its higher prevalence in children with COME as compared to non-affected children ([@B56]). Later studies have shown that human leukocyte antigen (HLA) 2 and HLA3 are strongly associated with AOM, while patients with COME have a lower frequency of HLA2 ([@B40], [@B39]). The heritability and genetic components of time with and the number of episodes with OME and AOM during the first 2 years of life were also investigated in a twin and a triplet study in 1999 and found a strong association between the duration or the number of episodes of OM and genetic makeup ([@B13]).

The contribution of genetics to OM susceptibility is supported by studies reporting a higher incidence of OM in children with chromosomal abnormalities. For example, the prevalence of OME in children with Down syndrome approaches 38% ([@B5]). Genes present on chromosome 21 in combination with craniofacial defects such as midfacial hypoplasia, short palate, and Eustachian tube dysfunction ([@B80]) and defects of the immune system ([@B66]) observed in children with Down syndrome may contribute to their increased risk of OM. *Ets1* gene, encoding a proto-oncogene, has been recently associated with craniofacial abnormalities and OM in a mouse study (see section Mouse and Mouse-to-Man Studies) ([@B12]). In humans, the *ETS2* gene that also belongs to the proto-oncogene gene family is present on chromosome 21 and may contribute to OM susceptibility in Down syndrome.

Several studies conducted on cohorts with Turner syndrome, a genetic disorder of partial or complete loss of chromosome X in females, described a highly variable (ranging from 9.1 to 91%) incidence of AOM ([@B78]; [@B11]). While the karyotype analysis did not reveal any significantly high-risk subgroup, females with Turner syndrome also have greater prevalence and longer duration of middle ear pathologies ([@B28]; [@B11]). These findings implicate some of the X chromosome genes in middle ear development, function, or health.

Mouse and Mouse-to-Man Studies {#S1.SS2}
------------------------------

The development and the phenotyping of transgenic and knockout mouse models in the last 30 years have significantly helped to identify several genes and genetic variations that confer susceptibility to OM in mice. Most of these mouse models spontaneously develop OM; studying their ear morphology and function provided insights into the disease pathophysiology at a molecular level. For instance, [@B24] showed that plasminogen (*Plg*)-deficient mice spontaneously develop chronic OM by 18 weeks of age. Plasmin, the active serine proteinase enzyme form of PLG, is mainly involved in the dissociation of fibrin clots and promotes the degradation of the extracellular matrix ([@B6]). Plasmin plays a critical role in several cellular processes, including wound healing, immunity, tissue remodeling, inflammation, and cell migration ([@B86]). Recent studies have shown that certain bacteria possess plasminogen-binding adhesions on their cell surface to exploit the fibrinolytic system, facilitating bacterial uptake and invasion ([@B68]; [@B6]).

The role of transcription factors in OM pathology became apparent through the studies of mutant mice lacking *Eya4*, *Evi1*, *Tgif*, *Ets1*, and *Fli1* genes ([@B35]; [@B64]; [@B19]; [@B85]; [@B12]). Mice lacking *Eya4* have Eustachian tube dysfunction, leading to an increased incidence of OME and hearing impairment ([@B19]). Variants in *Evi1* in *Junbo* mice have been shown to cause susceptibility to CSOM. *Junbo* mice accumulate middle ear effusions and develop hypoxia, inflammation, and thickening of the mucoperiosteum ([@B64]; [@B9]). Later studies have shown that the loss of BPIFA1, one of the most abundant secretory proteins in the upper respiratory tract ([@B58]), exacerbates the severity of OM in *Junbo* mice. While *Bpifa1* mutant mice did not show any OM susceptibility, the deletion of *Bpifa1* in mice carrying *Evi1 Junbo* variant leads to the thickening of the middle ear mucosa and an increase of collagen deposition ([@B57]). Loss of *Tgif1*, which encodes for TGIF1, results in OME accompanied by the thickening of the middle ear epithelial lining, an increase of goblet cell population, elevated levels of TNF-α and IL-1β in ear fluids, and conductive hearing loss in mice ([@B85]). Similarly, haploinsufficiency for *Ets1* and *Fli1* in mice results in craniofacial abnormalities, including a smaller middle ear cavity and fusion of ossicles to the walls of the middle ear ([@B12]). Furthermore, *Fli1*^±^ and *Ets1*^±^ double-mutant mice have hearing impairment and their middle ear mucosa is infiltrated by proinflammatory cells, leading to OM ([@B12]).

[@B34] showed that *Jeff* mutant mice carrying a *Fbxo11* variant have craniofacial abnormalities, elevated hearing thresholds, and middle ear effusion. Defects in the bulla cavitation were observed in *Fbxo11* mutant mice, which ultimately result in middle ear adhesions and soft tissue mineralization of the bony anatomy ([@B18]). Using N-ethyl-N-nitrosourea mutagenesis, [@B17] showed that the pathogenic variant, p.Leu972Pro, also known as *edison* variant, in the *Nischarin* (*Nisch*) gene leads to mild craniofacial defects, spontaneous OM by 20 weeks, and progressive hearing loss. Recent studies have reported the association of *TGIF1* and *NISCH* loci as potential risk areas for OM in humans ([@B10]), thus supporting the relevance of knowledge obtained from mouse models to the pathophysiology of OM in humans.

Finally, *Eda* and *Edar* transcription factors mutant mice (*Eda*^*Ta*^ and *Edar*^*dlJ/dlJ*^) also developed chronic rhinitis and OM ([@B7]). In these mutants, the nasopharyngeal glandular epithelium fails to develop, which leads to the loss of lysozyme secretion, the reduction of mucociliary clearance, and the overgrowth of commensal bacteria. The spread of nasal *S. aureus* in *Eda*^*Ta*^ mice and of *Escherichia coli* in *Edar*^*dlJ/dlJ*^ mice into the middle ear bulla potentially triggers inflammation and OM ([@B7]). A non-exhaustive list of the most common loci associated with OM in mouse is presented in [Table 1](#T1){ref-type="table"}.

Human Candidate Gene-Based and Genome-Wide Association Studies {#S1.SS3}
--------------------------------------------------------------

While early candidate gene-based OM studies have been done mostly on Caucasian patients with recurrent AOM and chronic OME (see section Early Studies), more recent genetic studies have been focusing on ethnic groups or communities for which marriages within the families are relatively common (e.g., indigenous Filipino community or Pakistani families) ([@B76], [@B75]). These studies have unveiled several novel genes and variants that confer susceptibility to familial OM (see section OM Susceptibility, Inbreeding, and Whole-Exome Sequencing): *A2ML1* and *FUT2* ([@B76], [@B75]).

Candidate Gene-Based Studies {#S1.SS4}
----------------------------

Many variants in the genome have been associated with infectious diseases ([@B42]). In some instances, the clinical features and the biological mechanisms -- such as immune response, inflammation, bacterial adhesion, viral infection, and mucociliary clearance -- involved in those infectious diseases are compatible with the mechanisms involved during an episode of OM, thus marking the genes known for these disorders as prime candidates for OM susceptibility and recurrence. Candidate gene-based studies on OM have mainly involved genes associated with innate immunity and inflammation ([@B74]). Those studies have been performed on cohorts from all over the world including US, Finland, Australia, Netherlands, Greece, and Belgium and have identified over 100 alleles that confer susceptibility to various forms of OM (see [Table 2](#T2){ref-type="table"} for the partial list of these alleles, genes, and associated clinical features). As evident from this non-exhaustive list, the identified genes belong to several different signaling cascades and developmental processes, including (a) immune response and inflammation (*MBL2*, *TLR2*, *TLR4*, *CD14*, *FCGR2A*, *TGFB1*, and *PAI1*) ([@B63]; [@B93], [@B94]; [@B23]; [@B46]; [@B37]; [@B32]), (b) cytokines (*IL6*, *IL10*, *IL1A*, *IL1B*, *TNFA*, and *IFNG*) ([@B65]; [@B4]; [@B69]; [@B37]), (c) tissue clearance (*SFPTA*, *SFTPA1*, *SFTPD*, *SLC11A1*, *MUC2*, *MUC5AC*, and *MUC5B*) ([@B67]; [@B74]; [@B73]; [@B51]), (d) transcriptional modulation (*SMAD2* and *SMAD4*) ([@B72]), (e) chemosensitivity (*CX3CR1*) ([@B60]), (f) protein modification (*CPT1A* and *FBXO11*) ([@B72], [@B71]), and (g) channel activity (*SCN1B*) ([@B74]). Some of these genes, such as *FBXO11*, have been replicated in several independent studies, which further strengthen their role in susceptibility to OM ([@B79]; [@B72]).

Genome-Wide Association Studies {#S1.SS5}
-------------------------------

Several genome-wide association studies (GWAS) have been performed to identify new common (frequency of 75% or greater) low-risk markers (OR \< 1.5) associated with OM subtypes. The findings of five salient GWAS are summarized here. In the Western Australian Pregnancy Cohort (Raine) study, a cohort of 416 patients prone to OM and 1,075 normal subjects was analyzed for 2,524,817 SNPs. Although the initial analysis revealed some association, no SNP reached GWAS significance (*P* \< 10^--8^) nor could be replicated both in the Australian or US cohorts ([@B71]; [@B3]). Intriguingly, the GWAS of the Minnesota and Pittsburg cohorts identified a SNP (rs10497394 on chromosome 2) that showed a significant association (GWAS discovery *P* = 1.30 × 10^--5^, independent otitis media population *P*~*meta*~ = 1.52 × 10^--8^) with susceptibility to either chronic OME or recurrent AOM ([@B2]). Finally, in a Finnish cohort (829 affected children and 2,118 randomly selected controls), the variants rs16974263 (GWAS discovery *P* = 1.77 × 10^--7^, sub-phenotype analysis *P*~*meta*~ = 2.92 × 10^--8^), rs268662 (*P* = 1.564 × 10^--6^), and rs4150992 (*P* = 3.37 × 10^--6^) were the most significant variants associated with COME ([@B22]). In [@B92] performed GWAS on a cohort of AOM children of European descent and reported a statistically significant association at 6q25.3 locus (rs2932989, *P*~*meta*~ = 2.15 × 10^--9^). This study further demonstrated that the associated variants are correlated with the methylation status (cg05678571, *p* = 1.43 × 10^--6^) and expression levels (*p* = 9.3 × 10^--5^) of the *FNDC1* gene. Also, an independent GWAS study on more than 200,000 individuals of European ancestry reported 14 genomic regions, including *FUT2* (*p*-value: 3.51 × 10^--30^), *TBX1* (1.17 × 10^--19^), *HLA-DRB1* (rs4329147, 9.55 × 10^--12^), *ABO* (3.67 × 10^--11^), *EFEMP1* (1.47 × 10^--10^), *AUTS2* (3.75 × 10^--9^), *CDHR3* (5.40 × 10^--9^), *BSN* (1.56 × 10^--8^), and *PLG* (3.78 × 10^--8^), that were significantly associated with childhood ear infection ([@B89]), further highlighting the contribution of genetic factors responsible for OM in humans.

OM Susceptibility, Inbreeding, and Whole-Exome Sequencing {#S1.SS6}
---------------------------------------------------------

### A2ML1 {#S1.SS6.SSS1}

In a large consanguineous indigenous Filipino pedigree with a high frequency of OM, [@B76] showed, by whole-exome and Sanger sequencing, that an 8 bp duplication in the *A2ML1* gene (LOD score of 7.5) was associated with susceptibility to OM. The same duplication was found in a heterozygous or a homozygous fashion in three individuals (European American and Hispanic) of another cohort of 123 children prone to OM and absent in non-otitis-prone children and more than 62,000 next-generation sequences. The authors identified seven additional heterozygous *A2ML1* variants in patients of European American and Hispanic American origin with OM. *A2ML1* encodes alpha-2-macroglobulin-like protein 1 (A2ML1), a protein that traps proteinases and cleaves them. A follow-up study identified 16 additional A2ML1 variants in OM subjects in indigenous Filipino and Pakistani families and US probands ([@B43]). Based on the expression in the murine mucosal epithelium of the middle ear, it has been speculated that A2ML1 may have a protective function by regulating the proteases present in the middle ear cavity and may also regulate the desquamation of epidermis ([@B27]). Recently, by 16S rRNA sequencing of the microbiota of the middle ear of an indigenous Filipino community prone to OM and segregating *A2ML1* variants, although not having a statistically significant difference between the cases and the controls, a taxonomic analysis revealed the relative abundance of the phyla *Fusobacteria* and *Bacteroidetes* and the genus *Fusobacterium* in *A2ML1* carriers compared to non-carriers ([@B77]).

### FUT2 {#S1.SS6.SSS2}

In the same large consanguineous indigenous Filipino pedigree with high frequency of OM, partly due to variants in *A2ML1*, a subset of individuals were wild type for *A2ML1* but were prone to OM ([@B76]). Further genetic analysis determined that the *FUT2* variant (p.Arg202^∗^, LOD score of 4.0) confer susceptibility to OM in those individuals ([@B75]). Screening of DNA samples from 609 additional multi-ethnic families and simplex case subjects with OM by direct Sanger sequencing, linkage analysis, Fisher exact, and transmission disequilibrium tests revealed several other *FUT2* variants (p.Arg138Cys, p.Trp154^∗^, and p.Ala104Val) that confer susceptibility to OM ([@B75]).

FUT enzymes are involved in the protein glycosylation pathway. FUTs transfer an L-fucose sugar derived from GDP-fucose (donor substrate) to a protein (acceptor substrate). The FUT family contains 13 members (FUT1--FUT13), and many of the FUTs are essential for the synthesis of blood group antigens. FUTs are single-pass type II membrane proteins, resident to the trans-Golgi, while the catalytic domain of FUT proteins resides in the lumen of the Golgi. In humans, *FUT1* and *FUT2* encode galactoside 2-L-fucosyltransferase, while *FUT3* encodes galactoside 3(4)-L-fucosyltransferase. FUT1 and FUT2 transfer L-fucose onto a β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosaminyl derivative and create the oligosaccharide FuC-alpha \[(1,2)Gal-beta-\], also known as H antigen, which is a soluble precursor essential for the final step in the soluble A and B antigen synthesis pathway. FUT3 transfers L-fucose onto a β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosaminyl derivative, or onto H antigen, in order to create blood group Lewis antigens.

*FUT1* and *FUT2* are differentially expressed in various cell types. For instance, *FUT1* expression is restricted to cells of mesodermal origin (for example, erythrocytes), and *FUT2* expression is being restricted to cells of endodermal origin (such as the middle ear mucosal cells). Therefore, A and B antigens will be expressed at the surface of red blood cells under the control of FUT1, while A and B antigens will be expressed at the surface of mucosal cells under the control of FUT2. Genetic variations in *FUT1* and *FUT2* naturally exist. Some *FUT1* and *FUT2* variants lead to non-functional enzymes, while certain variations in *FUT2* can also lead to a reduction of its expression ([@B75]). For instance, the FUT1 p.Tyr154Cys variant ablates the functional activity of the catalytic domain, resulting in the absence of A, B, or H antigens at the surface of erythrocytes (also known as the Bombay phenotype). Similarly, the FUT2 p.Trp154^∗^ variant causes absence of A, B, or H antigens at the surface of mucosal cells (a.k.a. non-secretor status) ([@B21], [@B20]). The p.Trp154^∗^ variant of FUT2 is also responsible for the non-secretor phenotype in European and African populations (47 and 42%, respectively).

A, B, and H and Lewis antigens are known to serve as an energy source while also regulating the adhesion of bacteria to the cell surface ([@B25]; [Figure 1](#F1){ref-type="fig"}). Intuitively, the different blood group antigens and their quantity at the surface of the cells of the mucosal epithelium of the middle ear would have an impact on the microbiota present in the middle ear cavity, and various blood types have been associated with OM ([@B95]). For instance, studies in a Finnish cohort reported a protective effect of blood type O against recurrent AOM, whereas blood type A was associated with increased risk for chronic OME ([@B95]). When tested *in vitro*, the four *FUT2* variants associated with OM (p.Ala104Val, p.Arg138Cys, p.Trp154^∗^, and p.Arg202^∗^) reduced the A antigen levels, while the two nonsense variants also reduced the FUT2 protein levels. Moreover, *Fut2* is transiently upregulated in the murine middle ear after inoculation with the non-typeable *H. influenza* ([@B75]). It is speculated that the OM-associated *FUT2* variants are modifying the middle ear microbiome through the regulation of A antigen levels in the middle ear mucosa, thus conferring susceptibility to OM ([@B75]).

![Role of *FUT2* in the regulation of blood group and Lewis antigens at the surface of ciliated cells of the middle ear mucosa: secretor and non-secretor status are illustrated. The imbalance of optimal bacteria (green) and pathogenic bacteria (red) is shown in a non-secretor individual that is prone to acute otitis media.](fgene-11-00313-g001){#F1}

While the microbial richness, structure, and composition differences were not statistically significant between the control individuals and the individuals prone to OM in the indigenous Filipino community segregating *FUT2* p.Arg202^∗^ variant, the individuals from a Colorado cohort prone to OM and carrier for the *FUT2* p.Trp154^∗^ variant had a relatively high abundance of *Lactobacillales* and *Gamma-proteobacteria* in their middle ears ([@B75]). Further studies in animal models are necessary to fully understand the FUT2-associated OM mechanism.

Conclusion {#S2}
==========

The current genetic and molecular data revealed the association of OM with deficits in each of the following mechanisms: (1) development of the middle ear cavity and Eustachian tube, (2) immune response, (3) bacterial adhesion and viral infection, (4) regulation of the extracellular matrix, and (5) clearance of the middle ear.

In [Figure 2](#F2){ref-type="fig"}, we have attempted to build a network that encompasses most of the known human proteins that have been associated with OM and our hypothesis about the potential impact on the microbiome of the middle ear cavity when these proteins are dysfunctional due to OM-associated genetic variants. Briefly, ABO and FUT2 are localized in the Golgi apparatus of the cells of the middle ear mucosa; these two proteins together create blood group Lewis antigens, potential sources of energy for microbiome. These antigens also provide an adhesion platform for the microbiota. Similarly, goblet cells secrete MUC5AC, MUC5B, MUC2 SFPTA, SFPTA1, and SFPTD to form mucus and surfactants in the middle ear cavity. Bacteria are present in these secretions and are cleared from the middle ear cavity by ciliated cells in order to maintain a healthy microbiome. Cells from the middle ear also secrete interleukins, chemokines, interferons, and necrosis and growth factors in order to recruit immune cells in the extracellular matrix. These cells fight infection and eliminate dead cells. During the inflammatory stage, the extracellular matrix is remodeled by proteases to allow immune cell infiltration. Those proteases are regulated and inhibited by A2ML1 and PAI1. A pathogenic genetic variation in any of those genes would eventually lead to middle ear infection and OM.

![Protein pathways contributing to otitis media (OM) in human: hypothetical network of human proteins in the middle ear mucosa that have been associated with OM. When these proteins are dysfunctional due to OM-associated genetic variants, they could potentially have an impact on the microbiota of the middle ear cavity.](fgene-11-00313-g002){#F2}

Future studies of the enrichment of certain microbiota in individuals with specific genetic variants may eventually help in identifying patients before chronic OM sets in or in devising a patient-specific treatment paradigm in the future.
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